• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients.乙酰化组蛋白阳性肝细胞的比例可指示肝硬化患者的功能状态和预后。
World J Gastroenterol. 2015 Jun 7;21(21):6665-74. doi: 10.3748/wjg.v21.i21.6665.
2
A revised scope in different prognostic models in cirrhotic patients: Current and future perspectives, an Egyptian experience.肝硬化患者不同预后模型的修订范围:当前与未来展望,埃及的经验
Arab J Gastroenterol. 2013 Dec;14(4):158-64. doi: 10.1016/j.ajg.2013.08.007. Epub 2013 Sep 29.
3
Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes.通过组蛋白乙酰化激活失活的肝细胞:肝细胞大量丢失后功能代偿的一种机制。
Am J Pathol. 2011 Sep;179(3):1138-47. doi: 10.1016/j.ajpath.2011.05.029. Epub 2011 Jul 16.
4
Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis.copeptin作为肝硬化血流动力学紊乱及预后的指标
PLoS One. 2015 Sep 17;10(9):e0138264. doi: 10.1371/journal.pone.0138264. eCollection 2015.
5
Copeptin is an independent prognostic factor for transplant-free survival in cirrhosis.copeptin 是肝硬化患者无移植生存的独立预后因素。
Liver Int. 2016 Apr;36(4):530-7. doi: 10.1111/liv.12992. Epub 2015 Nov 24.
6
Plasma copeptin, a possible prognostic marker in cirrhosis.血浆 copeptin,肝硬化的一种可能预后标志物。
Liver Int. 2013 Jul;33(6):843-51. doi: 10.1111/liv.12175. Epub 2013 Apr 7.
7
High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma.H3K9me3 高表达是唾液腺腺样囊性癌患者生存不良的强预测因子。
Arch Pathol Lab Med. 2013 Dec;137(12):1761-9. doi: 10.5858/arpa.2012-0704-OA.
8
Elaboration of tubules with active hedgehog drives parenchymal fibrogenesis in gestational alloimmune liver disease.具有活跃刺猬信号通路的小管形成驱动妊娠同种免疫性肝病中的实质纤维化。
Hum Pathol. 2015 Jan;46(1):84-93. doi: 10.1016/j.humpath.2014.09.010. Epub 2014 Oct 7.
9
Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis.口服葡萄糖耐量试验可预测肝硬化患者的预后。
Am J Gastroenterol. 2006 Jan;101(1):70-5. doi: 10.1111/j.1572-0241.2005.00307.x.
10
Cardiac and proinflammatory markers predict prognosis in cirrhosis.心脏和促炎标志物可预测肝硬化的预后。
Liver Int. 2014 Jul;34(6):e19-30. doi: 10.1111/liv.12428. Epub 2014 Jan 7.

引用本文的文献

1
The Role of Epigenetic Mechanisms in the Pathogenesis of Hepatitis C Infection.表观遗传机制在丙型肝炎感染发病机制中的作用。
Biomolecules. 2024 Aug 10;14(8):986. doi: 10.3390/biom14080986.
2
HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article.丙型肝炎病毒和肝细胞癌的探戈舞步——疾病复杂性的解析:一篇综述文章。
Int J Mol Sci. 2023 Nov 7;24(22):16048. doi: 10.3390/ijms242216048.
3
Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview.丙型肝炎病毒在肝细胞癌和神经疾病中的作用:综述
Front Oncol. 2022 Jul 29;12:913231. doi: 10.3389/fonc.2022.913231. eCollection 2022.
4
Role of Histone Post-Translational Modifications in Inflammatory Diseases.组蛋白翻译后修饰在炎症性疾病中的作用。
Front Immunol. 2022 Feb 24;13:852272. doi: 10.3389/fimmu.2022.852272. eCollection 2022.
5
Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC).丙型肝炎病毒诱导的肝细胞癌(HCC)中的表观遗传机制
Front Oncol. 2021 Jul 15;11:677926. doi: 10.3389/fonc.2021.677926. eCollection 2021.
6
Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease.用于肝病诊断和治疗的表观遗传生物标志物
Cancers (Basel). 2021 Mar 12;13(6):1265. doi: 10.3390/cancers13061265.
7
Predictive and preventive significance of AMPK activation on hepatocarcinogenesis in patients with liver cirrhosis.AMPK 激活对肝硬化患者肝癌发生的预测和预防意义。
Cell Death Dis. 2018 Feb 15;9(3):264. doi: 10.1038/s41419-018-0308-4.

本文引用的文献

1
The development and potential clinical utility of biomarkers for HDAC inhibitors.用于组蛋白去乙酰化酶抑制剂的生物标志物的开发及其潜在临床应用
Drug Discov Ther. 2013 Aug;7(4):129-36.
2
Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer.针对肺癌中组蛋白修饰剂的表观遗传疗法的临床前研究。
Front Oncol. 2013 Sep 9;3:235. doi: 10.3389/fonc.2013.00235.
3
Histone deacetylases as targets for treatment of multiple diseases.组蛋白去乙酰化酶作为治疗多种疾病的靶点。
Clin Sci (Lond). 2013 Jun;124(11):651-62. doi: 10.1042/CS20120504.
4
Histone deacetylases and cancer.组蛋白去乙酰化酶与癌症。
Mol Oncol. 2012 Dec;6(6):579-89. doi: 10.1016/j.molonc.2012.07.003. Epub 2012 Aug 27.
5
Liver regeneration.肝脏再生
J Hepatol. 2012 Sep;57(3):692-4. doi: 10.1016/j.jhep.2012.04.016. Epub 2012 May 18.
6
Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment.发展中国家的肝细胞癌:预防、诊断与治疗。
World J Hepatol. 2012 Mar 27;4(3):99-104. doi: 10.4254/wjh.v4.i3.99.
7
What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.肝纤维化有哪些新进展?肝纤维化中肌成纤维细胞的起源。
J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2(Suppl 2):65-8. doi: 10.1111/j.1440-1746.2011.07002.x.
8
In-hospital mortality among a cohort of cirrhotic patients admitted to a tertiary hospital.在一家三级医院住院的肝硬化患者队列中的住院死亡率。
Saudi J Gastroenterol. 2011 Nov-Dec;17(6):387-90. doi: 10.4103/1319-3767.87179.
9
Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes.通过组蛋白乙酰化激活失活的肝细胞:肝细胞大量丢失后功能代偿的一种机制。
Am J Pathol. 2011 Sep;179(3):1138-47. doi: 10.1016/j.ajpath.2011.05.029. Epub 2011 Jul 16.
10
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.慢性丙型肝炎病毒感染患者中 HCC 和肝硬化的患病率不断增加。
Gastroenterology. 2011 Apr;140(4):1182-1188.e1. doi: 10.1053/j.gastro.2010.12.032. Epub 2010 Dec 22.

乙酰化组蛋白阳性肝细胞的比例可指示肝硬化患者的功能状态和预后。

Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients.

作者信息

Zhou Ping, Xia Jie, Zhou Yong-Jie, Wan Jun, Li Li, Bao Ji, Shi Yu-Jun, Bu Hong

机构信息

Ping Zhou, Jie Xia, Yong-Jie Zhou, Jun Wan, Li Li, Ji Bao, Yu-Jun Shi, Hong Bu, Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

出版信息

World J Gastroenterol. 2015 Jun 7;21(21):6665-74. doi: 10.3748/wjg.v21.i21.6665.

DOI:10.3748/wjg.v21.i21.6665
PMID:26074705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4458777/
Abstract

AIM

To investigate whether the proportions of acetyl-histone-positive hepatocytes could be used as markers of deteriorating liver function.

METHODS

In total, 611 cirrhotic cases from 3701 patients who were diagnosed during the past 15 years were screened, and 152 follow-up cases were selected. Paraffin tissue microarray was prepared for immunohistochemistry to examine acetyl-histone expression. The proportions of positive hepatocytes were recorded, and their correlations to clinical and laboratory indicators were analyzed statistically.

RESULTS

The proportions of H2AK5ac(+), H3K9/K14ac(+) and H3K27ac(+) hepatocytes gradually increased with deteriorating liver function and with increasing levels of serum markers of liver injury. In the follow-up cases, patients with > 70% H2AK5ac(+), H3K9/K14ac(+) or H3K27ac(+) hepatocytes had statistically lower survival rates (P < 0.05). Furthermore, > 70% H2AK5ac(+) or H3K27ac(+) hepatocytes were strong independent predictors of overall survival (P < 0.05).

CONCLUSION

The proportions of acetyl-histone-positive hepatocytes are closely associated with the liver function and prognosis of cirrhotic patients.

摘要

目的

研究乙酰化组蛋白阳性肝细胞的比例是否可作为肝功能恶化的标志物。

方法

对过去15年中确诊的3701例患者中的611例肝硬化病例进行筛选,并选取152例进行随访。制备石蜡组织芯片进行免疫组化以检测乙酰化组蛋白的表达。记录阳性肝细胞的比例,并对其与临床和实验室指标的相关性进行统计学分析。

结果

H2AK5ac(+)、H3K9/K14ac(+)和H3K27ac(+)肝细胞的比例随着肝功能恶化和肝损伤血清标志物水平升高而逐渐增加。在随访病例中,H2AK5ac(+)、H3K9/K14ac(+)或H3K27ac(+)肝细胞比例>70%的患者生存率在统计学上较低(P<0.05)。此外,H2AK5ac(+)或H3K27ac(+)肝细胞比例>70%是总生存的强有力独立预测因素(P<0.05)。

结论

乙酰化组蛋白阳性肝细胞的比例与肝硬化患者的肝功能及预后密切相关。